Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation
Gerotziafas GT, Petropoulou AD, Verdy E, et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5: 955-962.
Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor
Lisman T, Adelmeijer J, Nieuwenhuis HK, et al. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Co-agul Fibrinolysis 2003; 14: 557-562.
Hyperpro-thrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism
Colucci M, Binetti BM, Tripodi A, et al. Hyperpro-thrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103: 2157-2161.
Profibrino-lytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots
Semeraro F, Piro D, Rossiello MR, et al. Profibrino-lytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots. Thromb Haemost 2007; 98: 1208-1214.
The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif - the C-domain
Al Dieri R, Wagenvoord R, van Dedem GW, et al. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif - the C-domain. J Thromb Haemost 2003; 1: 907-914.
Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface
Ghosh S, Ezban M, Persson E, et al. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 2007; 5: 336-346.
Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. II. Effects on f ibrinolysis
Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. II. Effects on f ibrinolysis. J Biol Chem 2002; 277: 50445-50449.
Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism
Schutgens RE, Esseboom EU, Snijder RJ, et al. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. J Lab Clin Med 2004; 144: 100-107.
